Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2013-04-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)
NCT01863693
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT01932125
Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer
NCT01982500
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
NCT00937560
An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer
NCT02151370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Use of bevacizumab (Avastin ®) - First-line ovarian cancer
Patient receiving bevacizumab in ovarian cancer first line treatment
Bevacizumab
Observation of bevacizumab administration in first line ovarian cancer treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Observation of bevacizumab administration in first line ovarian cancer treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive bevacizumab (Avastin ®) in first-line therapy
* Patients should be informed of the study orally and should not have any objection their data to be processed.
Exclusion Criteria
* Patient non-affiliated to a social security scheme.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roche Pharma AG
INDUSTRY
ARCAGY/ GINECO GROUP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dominique BERTON-RIGAUD, MD
Role: PRINCIPAL_INVESTIGATOR
ICO de l'Ouest, Site René Gauducheau - Saint-Herblain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Paul Papin
Angers, , France
Clinique Tivoli
Bordeaux, , France
Institut Bergonié
Bordeaux, , France
Centre jean Perrin
Clermont-Ferrand, , France
Centre Hospitalier Intercommunal
Fréjus, , France
institut Paoli Calmette
Marseille, , France
Clinique Valdegour
Nîmes, , France
Centre Hospitalier Régional
Orléans, , France
Arcagy-Gineco
Paris, , France
Centre Hospitalier Lyon-sud
Pierre-Bénite, , France
Institut Jean Godinot
Reims, , France
Clinique Armoricaine de Radiologie
Saint-Brieuc, , France
ICO René Gauducheau
Saint-Herblain, , France
Hôpital Civil
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Berton D, Floquet A, Lescaut W, Baron G, Kaminsky MC, Toussaint P, Largillier R, Savoye AM, Alexandre J, Delbaldo C, Malaurie E, Barletta H, Bosacki C, Garnier-Tixidre C, Follana P, Laharie-Mineur H, Briac Levache C, Valenza B, Dechartres A, Mollon-Grange D, Selle F. Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients. Front Pharmacol. 2021 Sep 20;12:711813. doi: 10.3389/fphar.2021.711813. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENCOURAGE (GINECO-OV123)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.